Genetic extinction or pharmacological inhibition of KRAS* resulted in up-regulation of ERBB2 and ERBB3 expression in human and murine models, which prompted cancer cell utilization of cancer-associated fibroblast-derived NRG1 as a survival factor.
[Genes & Development]
